Form 4: Clover Health CEO Reports RSU Tax Withholding

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, reported the automatic withholding of shares to cover tax obligations related to RSU vestings on December 14 and 15, 2025.

Summary

• Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. (CLOV), reported two dispositions of Class A Common Stock.
• On December 14, 2025, 12,567 shares were automatically withheld at a price of $2.7 per share to cover tax obligations upon the vesting of restricted stock units (RSUs) originally granted on March 14, 2022.
• On December 15, 2025, 8,691 shares were automatically withheld at a price of $2.7 per share to cover tax obligations upon the vesting of restricted stock units (RSUs) originally granted on September 16, 2022.
• These transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-arranged.
• Following these reported transactions, Jamie L. Reynoso beneficially owns 2,772,153 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: This is a neutral filing, reporting routine executive compensation events (RSU vesting and tax withholding). It does not contain information that would significantly alter the company's fundamental outlook or financial health, nor does it suggest any new positive or negative developments beyond the expected course of executive equity management.

Positives

• The transactions represent the vesting of previously granted restricted stock units, indicating continued compensation for the executive.
• The use of a Rule 10b5-1(c) plan demonstrates pre-planned transactions, which can reduce concerns about opportunistic insider trading.

Negatives

• The disposition of shares, even for tax purposes, results in a slight reduction in the executive's direct beneficial ownership.

Risks

• Future stock price fluctuations could impact the value of the executive's remaining beneficial ownership.
• Continued service is required for future RSU vestings, posing a risk if employment ceases before the final vesting dates.

Future Outlook

The filing indicates that remaining restricted stock units (RSUs) will continue to vest quarterly in equal installments of 6.25% until March 14, 2026, for the first grant, and until September 15, 2026, for the second grant, contingent on the reporting person's continued service.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation-related stock transactions. It reflects standard practices for publicly traded companies where restricted stock units are a common component of executive pay, vesting over time and often involving automatic share withholding for tax purposes. It does not provide specific insights into Clover Health's operational performance or competitive position within the Medicare Advantage sector, but rather details an individual executive's equity movements.

Comparison to Industry Standards

• The RSU vesting and subsequent tax withholding are standard practices for executive compensation across the healthcare and technology industries.
• Companies like UnitedHealth Group (UNH), Humana (HUM), and other Medicare Advantage providers frequently use RSUs as a long-term incentive, with similar tax withholding mechanisms upon vesting.
• The specific vesting schedule (quarterly 6.25% installments) is also a common approach to retain executives over several years.

Stakeholder Impact

• Shareholders: Minor dilution from the original RSU grants is already factored into the company's equity structure; the tax withholding is a mechanical event. The executive's continued equity ownership aligns interests with shareholders.
• Employees: No direct impact on general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Remaining RSUs from the March 14, 2022 grant will continue to vest quarterly in 6.25% installments until March 14, 2026, subject to continued service.
• Remaining RSUs from the September 16, 2022 grant will continue to vest quarterly in 6.25% installments until September 15, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax withholding) and does not provide new information regarding Clover Health's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are expected and do not indicate a shift in insider sentiment or company fundamentals. Therefore, a 'hold' recommendation is appropriate, pending further substantive company announcements.

Keywords

Clover Health, CLOV, Form 4, Insider Transaction, Jamie L. Reynoso, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Medicare Advantage